Business
Easton Pharmaceuticals Is Provided a Manufacturing, Regulatory Filing Update and Forward Sales Estimates for VIORRA
Easton Pharmaceuticals Is Provided a Manufacturing, Regulatory Filing Update and Forward Sales Estimates for VIORRA.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Is Provided a Manufacturing, Regulatory Filing Update and Forward Sales Estimates for VIORRA\n \n \nEaston Pharmaceuticals Is Provided a Manufacturing, Regulatory Filing Update and Forward Sales Estimates for VIORRA\n \n TORONTO, ON--(Marketwired - Nov 4, 2013) - Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products announced today an update to its recently announced regulatory filing in Mexico for its Viorra product through BMV Medica S.A. de C.V. (BMV), a Mexican Regulatory & Licensing consultancy in Mexico, Latin America and South-East Asia.\n As previously announced, BMV Medica S.A. de C.V. has estimated the regulatory submission in Mexico will require six to seven months until an anticipated marketing approval is obtained. According to BMV, discussions on Easton's behalf have been initiated to source a distribution partner within Mexico. In addition, BMV has advised Easton they have also sourced out a product specific US FDA-approved manufacturing partner and facility within Mexico which they believe could be more cost effective and better suited to manufacture Viorra and other products. Although Easton has previously sourced out a manufacturing company for Viorra and any of its other products including other products presently under discussion, BMV believes its Mexico manufacturer is better suited for the Company's needs as well as providing a boost to its regulatory filing with the Mexican government. It is anticipated that Easton will be making a decision on its manufacturing partner within the next 30 days which will be required for the regulatory submission. \n BMV has provided what it believes to be realistic projections towards possible sales figures that could be attained once an approval has been granted by regulatory authorities in Mexico. BMV believes an approval in Mexico would allow for instantaneous approvals and acceptance by governments in other parts of Latin America which opens up another huge potential market for VIORRA. According to BMV, Sales targets could reach between $10 to $14 million USD within 24 months of launch. These projections are based around other previously approved products, the size of the market, and the belief that a VIORRA t...